Accession Number:

ADA612750

Title:

Biological and Clinical Characterization of Novel lncRNAs Associated with Metastatic Prostate Cancer

Descriptive Note:

Annual rept. 15 Aug 2013-14 Aug 2014

Corporate Author:

MICHIGAN UNIV REGENTS ANN ARBOR DIV OF RESEARCH DEVELOPMENT AND ADMINISTRATION

Personal Author(s):

Report Date:

2014-10-01

Pagination or Media Count:

49.0

Abstract:

LncRNA are polyadenylated RNA species that are more than 200bp in length and are implicated in development of variety of cancers including prostate cancer. In this study we have identified PCAT29 as the first androgen receptor repressed lncRNA that functions as a tumor suppressor. We show that loss of PCAT29 may identify a subset of patients at higher risk for disease recurrence. Collectively, PCAT29 is a tumor-suppressive lncRNA of prognostic and therapeutic relevance in prostate cancer. In addition, we have performed transcriptome analysis to identify a set of AR regulated lncRNAs. AR plays a critical role in the development and progression of prostate cancer. AR regulates a large repertoire of genes however, its role in Long non-coding RNAs lncRNA regulation remains unclear. With this compendium of AR regulated lncRNA, we will be able to identify lncRNAs that play important role in prostate cancer development and progression.

Subject Categories:

  • Biochemistry
  • Genetic Engineering and Molecular Biology
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE